Comparative Pharmacology
Head-to-head clinical analysis: STENDRA versus VARDENAFIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STENDRA versus VARDENAFIL HYDROCHLORIDE.
STENDRA vs VARDENAFIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation in corpus cavernosum, leading to smooth muscle relaxation and increased penile blood flow.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum, thereby facilitating penile erection.
50 mg orally once daily as needed, 1 hour before sexual activity. Maximum dose 100 mg. Maximum frequency once daily.
10 mg orally once daily as needed, approximately 60 minutes before sexual activity; maximum dose 20 mg; maximum frequency once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours in healthy subjects; may be prolonged in hepatic impairment (Child-Pugh B: up to 6 hours) or with concomitant CYP3A4 inhibitors.
Terminal elimination half-life is approximately 4-5 hours in healthy subjects. In elderly patients (≥65 years) or those with hepatic impairment (Child-Pugh A/B), half-life may be prolonged up to 6-8 hours.
Fecal (approximately 63%) and renal (approximately 21%) as metabolites; less than 2% excreted unchanged in urine.
Primarily hepatic metabolism (CYP3A4, minor CYP2C9) followed by fecal excretion (approximately 91-95% of dose as metabolites) and renal excretion (approximately 2-6% as unchanged drug).
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor